Position in EXEL
as of Jun 30, 2026
· filed Aug 5, 2026
Position Value
$253,060
-$85,084 QoQ
Shares Held
4,651
-41.0% QoQ
Ownership
0.002%
of shares outstanding
% of Portfolio
0.04%
of 13F equity value
Holder Rank
#548
of 751 holders
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026111 Capital holds $6,048,567 across 9 Biotechnology names. EXEL ranks #8 (4.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
3,185 | $1,985,974 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
3,080 | $1,529,928 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
2,412 | $726,084 | |
| 4 | AXSM |
Axsome Therapeutics, Inc.
|
1,839 | $450,132 | |
| 5 | HALO |
Halozyme Therapeutics, Inc.
|
4,826 | $377,731 | |
| 6 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
4,587 | $373,886 | |
| 7 | INCY |
Incyte Corp
|
2,255 | $255,626 | |
| 8 | EXEL |
Exelixis, Inc.
This page
|
4,651 | $253,060 |
All Filings in EXEL
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $253,060 | 4,651 | Shares | Sole | 2026-08-05 | |
| 2026-03-31 | $338,144 | 7,884 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $215,731 | 4,922 | Shares | Sole | 2026-02-11 | |
| 2025-06-30 | $235,254 | 5,337 | Shares | Sole | 2025-07-21 | |
| No filing history on record for this holder in this stock. | ||||||